A phase I trial of recombinant human gamma interferon (IFN-γ4A) in patients with advanced malignancy

Ruben Perez, Allan Lipton, Harold A. Harvey, Mary A. Simmonds, Paula J. Romano, Sharon L. Imboden, Gina Giudice, Michael R. Downing, N. K. Alton

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We report a Phase I study in 39 cancer patients of the tolerance and biologic activity of 47 intravenous (i.v.), intramuscular (i.m.), and subcutaneous (s.c.) treatments with recombinant methional gamma interferon (IFN-γ4A) which most closely resembles the natural material produced by T lymphocytes. Patients were treated with IFN-γ4A 5 days a week for 2 weeks. After a 2-week rest period, patients were placed on the same dose of drug three times a week. The most common side effects—fever, chills, malaise, myalgias, and nausea and vomiting—were seen with all routes of administration. Reversible increases in hepatic transaminase and decrease in granulocytes counts were seen. The dose-limiting toxicities observed were malaise and orthostatic hypotension. The maximum tolerated dose was 500–1,000 μg/M2/day. The t1/2 of IFN-γ4A in the circulation was 20 min after i.v. injection. No blood levels were detected after i.m. or s.c. injection. Antibody against IFN-γ4A increased in three patients. A complete response was observed in one patient with pulmonary metastases from renal cell carcinoma.

Original languageEnglish (US)
Pages (from-to)309-317
Number of pages9
JournalJournal of Biological Response Modifiers
Volume7
Issue number3
StatePublished - Jun 1988

Fingerprint

Neoplasms
Chills
Orthostatic Hypotension
Maximum Tolerated Dose
Myalgia
Intramuscular Injections
Subcutaneous Injections
Transaminases
Renal Cell Carcinoma
Granulocytes
Intravenous Injections
Nausea
interferon gamma-4A
Neoplasm Metastasis
T-Lymphocytes
Lung
Antibodies
Liver
Pharmaceutical Preparations
Therapeutics

All Science Journal Classification (ASJC) codes

  • Immunology
  • Pharmacology
  • Cancer Research

Cite this

Perez, Ruben ; Lipton, Allan ; Harvey, Harold A. ; Simmonds, Mary A. ; Romano, Paula J. ; Imboden, Sharon L. ; Giudice, Gina ; Downing, Michael R. ; Alton, N. K. / A phase I trial of recombinant human gamma interferon (IFN-γ4A) in patients with advanced malignancy. In: Journal of Biological Response Modifiers. 1988 ; Vol. 7, No. 3. pp. 309-317.
@article{349607a134f44bc7b5e64b7f8d0d87aa,
title = "A phase I trial of recombinant human gamma interferon (IFN-γ4A) in patients with advanced malignancy",
abstract = "We report a Phase I study in 39 cancer patients of the tolerance and biologic activity of 47 intravenous (i.v.), intramuscular (i.m.), and subcutaneous (s.c.) treatments with recombinant methional gamma interferon (IFN-γ4A) which most closely resembles the natural material produced by T lymphocytes. Patients were treated with IFN-γ4A 5 days a week for 2 weeks. After a 2-week rest period, patients were placed on the same dose of drug three times a week. The most common side effects—fever, chills, malaise, myalgias, and nausea and vomiting—were seen with all routes of administration. Reversible increases in hepatic transaminase and decrease in granulocytes counts were seen. The dose-limiting toxicities observed were malaise and orthostatic hypotension. The maximum tolerated dose was 500–1,000 μg/M2/day. The t1/2 of IFN-γ4A in the circulation was 20 min after i.v. injection. No blood levels were detected after i.m. or s.c. injection. Antibody against IFN-γ4A increased in three patients. A complete response was observed in one patient with pulmonary metastases from renal cell carcinoma.",
author = "Ruben Perez and Allan Lipton and Harvey, {Harold A.} and Simmonds, {Mary A.} and Romano, {Paula J.} and Imboden, {Sharon L.} and Gina Giudice and Downing, {Michael R.} and Alton, {N. K.}",
year = "1988",
month = "6",
language = "English (US)",
volume = "7",
pages = "309--317",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

Perez, R, Lipton, A, Harvey, HA, Simmonds, MA, Romano, PJ, Imboden, SL, Giudice, G, Downing, MR & Alton, NK 1988, 'A phase I trial of recombinant human gamma interferon (IFN-γ4A) in patients with advanced malignancy', Journal of Biological Response Modifiers, vol. 7, no. 3, pp. 309-317.

A phase I trial of recombinant human gamma interferon (IFN-γ4A) in patients with advanced malignancy. / Perez, Ruben; Lipton, Allan; Harvey, Harold A.; Simmonds, Mary A.; Romano, Paula J.; Imboden, Sharon L.; Giudice, Gina; Downing, Michael R.; Alton, N. K.

In: Journal of Biological Response Modifiers, Vol. 7, No. 3, 06.1988, p. 309-317.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A phase I trial of recombinant human gamma interferon (IFN-γ4A) in patients with advanced malignancy

AU - Perez, Ruben

AU - Lipton, Allan

AU - Harvey, Harold A.

AU - Simmonds, Mary A.

AU - Romano, Paula J.

AU - Imboden, Sharon L.

AU - Giudice, Gina

AU - Downing, Michael R.

AU - Alton, N. K.

PY - 1988/6

Y1 - 1988/6

N2 - We report a Phase I study in 39 cancer patients of the tolerance and biologic activity of 47 intravenous (i.v.), intramuscular (i.m.), and subcutaneous (s.c.) treatments with recombinant methional gamma interferon (IFN-γ4A) which most closely resembles the natural material produced by T lymphocytes. Patients were treated with IFN-γ4A 5 days a week for 2 weeks. After a 2-week rest period, patients were placed on the same dose of drug three times a week. The most common side effects—fever, chills, malaise, myalgias, and nausea and vomiting—were seen with all routes of administration. Reversible increases in hepatic transaminase and decrease in granulocytes counts were seen. The dose-limiting toxicities observed were malaise and orthostatic hypotension. The maximum tolerated dose was 500–1,000 μg/M2/day. The t1/2 of IFN-γ4A in the circulation was 20 min after i.v. injection. No blood levels were detected after i.m. or s.c. injection. Antibody against IFN-γ4A increased in three patients. A complete response was observed in one patient with pulmonary metastases from renal cell carcinoma.

AB - We report a Phase I study in 39 cancer patients of the tolerance and biologic activity of 47 intravenous (i.v.), intramuscular (i.m.), and subcutaneous (s.c.) treatments with recombinant methional gamma interferon (IFN-γ4A) which most closely resembles the natural material produced by T lymphocytes. Patients were treated with IFN-γ4A 5 days a week for 2 weeks. After a 2-week rest period, patients were placed on the same dose of drug three times a week. The most common side effects—fever, chills, malaise, myalgias, and nausea and vomiting—were seen with all routes of administration. Reversible increases in hepatic transaminase and decrease in granulocytes counts were seen. The dose-limiting toxicities observed were malaise and orthostatic hypotension. The maximum tolerated dose was 500–1,000 μg/M2/day. The t1/2 of IFN-γ4A in the circulation was 20 min after i.v. injection. No blood levels were detected after i.m. or s.c. injection. Antibody against IFN-γ4A increased in three patients. A complete response was observed in one patient with pulmonary metastases from renal cell carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0023918382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023918382&partnerID=8YFLogxK

M3 - Article

C2 - 3134513

AN - SCOPUS:0023918382

VL - 7

SP - 309

EP - 317

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 3

ER -